Contact UsInvestorsCareersMediaScienceContact Us
HomeMedia Centre

Media Centre 

10.15.24
An Van Gerven Is Appointed President of Pfizer Canada
08.10.24
Pfizer Canada and the Skin Spectrum Summit Announce 2024 Recipients of the Canadian Skin of Colour & Diversity Scholarship
24.09.24
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
19.09.24
ABRYSVO™: Pfizer Canada’s Newly Publicly Funded Vaccine a Step Towards National RSV Prevention in Older Adults
22.08.24
PADCEV (enfortumab vedotin) in combination with pembrolizumab approved by Health Canada to treat advanced bladder cancer
12.08.24
Pfizer Canada Ranked #1 by 100 Canadian Patient Advocacy Groups
03.06.24
National Campaign Encourages Canadians to go “Out of Office” This Migraine Awareness Month
03.06.24
Pfizer invests $4.9M in McMaster University study to help improve care for multiple myeloma patients in Canada
22.05.24
Pfizer Announces Availability of ABRYSVOTM in Canada for Immunization of Pregnant Individuals and Adults 60+
24.04.24
VELSIPITY™ Receives Health Canada Approval for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
23.04.24
Pfizer Canada and McMaster University to foster health equity in vaccine science
04.04.24
NURTEC ODT® is Now Available in Canada for the Treatment of Acute Migraine
27.02.24
Pfizer Canada named one of Montreal’s Top Employers for 2024
20.02.24
Crohn’s and Colitis Canada and Pfizer Canada Introduce the 2024 Diversity, Equity and Inclusion Awards Program in IBD Research
13.02.24
ELREXFIO™ is authorized by Health Canada for adults with relapsed or refractory multiple myeloma in Canada
31.01.24
Sumitomo Pharma and Pfizer Canada Announce Availability of MYFEMBREE® in Canada
23.01.24
Pfizer Canada named one of Canada’s Top Employers for Young People for 2024
04.01.24
Health Canada Approves Pfizer’s Bivalent Respiratory Syncytial Virus (RSV) Vaccine for Older Adults and Infants Through Maternal Immunization
03.01.24Health Canada approves Pfizer Canada’s gene therapy
in hemophilia B
04.12.23LITFULO™ Receives Health Canada Approval, Becoming the First Approved Treatment for Severe Alopecia Areata in Canada27.11.23Pfizer Canada, Colorectal Cancer Canada and Thermo Fisher Scientific announce recipients of colorectal cancer grant15.11.23Pfizer and BioNTech Receive Prestigious Prix Galien Canada Innovative Product Award for COMIRNATY, Canada’s First Approved COVID-19 Vaccine06.11.23Crohn’s and Colitis Canada and Pfizer Canada Announce 2023 Women in IBD Award Recipients02.11.23The Lung Health Foundation, Lung Cancer Canada, the Quebec Lung Association and Pfizer Canada announce recipients of the 2023 national Quality Improvement grant program to support Canadians living with lung cancer23.10.23Pfizer Canada and the Skin Spectrum Summit reveal recipients of new scholarship to improve dermatological care for racialized Canadians19.10.23Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE®16.10.23Pfizer Canada Invests in Canadian Innovation, Announcing Winners of Open Call for Healthcare Solutions28.09.23
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine31.07.23Rethink Breast Cancer and Pfizer Canada announce recipients of the 2023 national quality improvement grants to support metastatic breast cancer patients17.07.23Pfizer Canada and the Skin Spectrum Summit announce a new scholarship to improve dermatological care for racialized Canadians06.06.23Pfizer Canada and the Canadian Cardiovascular Society announce recipients of research fellowship awards focused on Transthyretin Amyloid Cardiomyopathy (ATTR-CM)17.05.23Pfizer Canada Launches National Initiative to Propel Startup Solutions for Key Challenges in Healthcare14.04.23Pfizer Canada Initiates Submission to Health Canada for Its Bivalent Respiratory Syncytial Virus (RSV) Vaccine08.03.23Women in Governance Awards Gold Level Gender Parity Certification to Pfizer Canada  03.02.23National Advisory Committee on Immunization NACI) provides strong recommendation for PREVNAR 20 09.12.22Pfizer and BioNTech's Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age07.11.22Crohn's and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients03.11.22Canadian Paralympic Committee and Pfizer Canada renew long-time commitment to growing Paralympic Movement through 202518.10.22Together with Bladder Cancer Canada, EMD Serono and Pfizer Canada announce inaugural recipients of national quality improvement grants......07.10.22Pfizer and BioNTech's Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine ......

If you are a member of the media with specific questions about our Canadian operations, please call 1-866-9Pfizer (1 866 973-4937) or email [email protected] to reach a member of the Pfizer Canada Corporate Affairs team. To stay up to date on Pfizer Canada news, follow us on social media:

About UsOur ProductsHelping Communities Our Voice Suppliers Distribution ChannelPfizer WorldwideMedia CentreTerms Of Use Careers Healthcare ProfessionalsContact UsPrivacy PolicyCopyright © Pfizer Canada 2022 All rights reserved. The information is intended only for residents of Canada. ® Pfizer Inc, used under license